TGA Seeks Views on Stronger Vitamin B6 Labels for Low-Risk Medicines
The Therapeutic Goods Administration (TGA) is proposing stricter labeling requirements for low-risk medicines containing vitamin B6 to prevent nerve damage from excessive intake. The move follows a decision to reclassify higher-dose B6 supplements as 'pharmacist only' starting in 2027.
Why it matters
This regulatory change aims to improve public health safety by increasing consumer awareness of the risks associated with common over-the-counter supplements.
The Therapeutic Goods Administration (TGA) is seeking feedback through a public consultation - external site on its proposal to strengthen the labelling of low-risk products that contain vitamin B6.
This includes stronger warning statements and clearer labelling that indicates the presence and amount of vitamin B6 in these products.
The consultation forms part of the TGA's efforts to help Australians reduce excessive vitamin B6 intake and thereby minimise the potential risk of harm.
Too much of this vitamin can increase the risk of nerve damage, which can cause severe, debilitating and potentially long-term effects.
If introduced, new labelling requirements would apply to listed medicines that contain vitamin B6, specifically the following ingredients:
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in